Health Junshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free… James Pereira Apr 21, 2023 <!-- Name:DistributionId Value:8812412 --> <!--… Read More...
Health Neoadjuvant Combo Immunotherapy Studied in Resectable Melanoma James Pereira Oct 29, 2022 Physician’s Briefing Staff FRIDAY, Oct. 28, 2022 (HealthDay News) -- For patients… Read More...
Health Neoadjuvant Anti-PD-1 Strategy Prevails Over Adjuvant in Resectable Melanoma James Pereira Sep 14, 2022 PARIS -- The randomized trial data have spoken, and they… Read More...
Health Neoadjuvant Cemiplimab Active in Resectable Cutaneous Squamous Cell Carcinoma James Pereira Sep 13, 2022 PARIS -- Neoadjuvant therapy with cemiplimab (Libtayo)… Read More...
Health Apexigen Presents New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in… James Pereira Sep 10, 2022 SAN CARLOS, Calif., Sept. 10, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused… Read More...
Health Trials Affirm Value of Immunotherapy in Resectable NSCLC James Pereira Aug 23, 2022 Two studies shed light on the impact of… Read More...
Health Neoadjuvant Chemo Plus Immunotherapy in Resectable NSCLC James Pereira Jun 16, 2022 At the recent American Society of… Read More...
Health Boosting Responses to Neoadjuvant Therapy in Resectable NSCLC James Pereira Apr 13, 2022 NEW ORLEANS -- Neoadjuvant combinations involving durvalumab… Read More...
Health Atezolizumab Regimen Safe in Resectable Mesothelioma James Pereira Oct 1, 2021 Use of atezolizumab (Tecentriq) as part… Read More...
Health Triplet Therapy Proves Safe in Resectable Malignant Pleural Mesothelioma James Pereira Sep 13, 2021 A three-agent neoadjuvant regimen met safety criteria, with… Read More...